A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study

被引:8
|
作者
Qurashi, Inti [1 ]
Chaudhry, Imran B. [2 ,3 ,4 ]
Khoso, Ameer B. [4 ]
Husain, Muhammad Omair [5 ,6 ]
Hafeez, Danish [7 ]
Kiran, Tayyeba [4 ]
Lane, Steven [8 ]
Naqvi, Haider A. [9 ]
Minhas, Fareed A. [10 ]
Nizami, Asad Tamizuddin [10 ]
Razzaque, Bushra [10 ]
Bokhari, Sumira Qambar [11 ]
Yung, Alison R. [12 ,13 ]
Deakin, Bill [14 ]
Husain, Nusrat [2 ,15 ]
机构
[1] Univ Liverpool, Inst Populat Hlth, Liverpool, England
[2] Univ Manchester, Div Psychol & Mental Hlth, Manchester, England
[3] Ziauddin Univ, Dept Psychiat, Karachi, Pakistan
[4] Pakistan Inst Living & Learning, Karachi, Pakistan
[5] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[7] Homerton Univ Hosp, London, England
[8] Univ Liverpool, Inst Translat Med, Liverpool, England
[9] Dow Univ Hlth Sci, Dept Psychiat, Karachi, Pakistan
[10] Rawalpindi Med Univ, Inst Psychiat, Rawalpindi, Pakistan
[11] Serv Inst Med Sci, Dept Psychiat & Behav Sci, Lahore, Pakistan
[12] Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic, Australia
[13] Orygen, Parkville, Vic, Australia
[14] Univ Manchester, Sch Biol Sci, Div Neurosci & Expt Psychol, Manchester, England
[15] Mersey Care NHS Fdn Trust, Prescot, England
关键词
Early intervention; Psychosis; Minocycline; Omega-3; At-risk mental state; Inflammation; POLYUNSATURATED FATTY-ACIDS; PSYCHOTIC DISORDERS; YOUNG-PEOPLE; SCHIZOPHRENIA; VERSION; ONSET;
D O I
10.1016/j.bbi.2023.10.025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Inflammatory mechanisms are thought to contribute to the onset of psychosis in persons with an at -risk mental state (ARMS). We investigated whether the anti-inflammatory properties of minocycline and omega -3 polyunsaturated fatty acids (omega-3), alone or synergistically, would prevent transition to psychosis in ARMS in a randomised, double-blind, placebo-controlled trial in Pakistan.Methods: 10,173 help-seeking individuals aged 16-35 years were screened using the Prodromal Questionaire-16. Individuals scoring 6 and over were interviewed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) to confirm ARMS. Participants (n = 326) were randomised to minocycline, omega-3, combined minocycline and omega-3 or to double placebo for 6 months. The primary outcome was transition to psychosis at 12 months.Findings: Forty-five (13.8 %) participants transitioned to psychosis. The risk of transition was greater in those randomised to omega-3 alone or in combination with minocycline (17.3.%), compared to 10.4 % in those not exposed to omega-3; a risk-ratio (RR) of 1.67, 95 % CI [0.95, 2.92] p = 0.07. The RR for transitions on mino-cycline vs. no minocycline was 0.86, 95 % CI [0.50, 1.49] p > 0.10. In participants who did not become psychotic, CAARMS and depression symptom scores were reduced at six and twelve months (mean CAARMS difference = 1.43; 95 % CI [0.33, 1.76] p < 0.01 in those exposed to omega-3. Minocycline did not affect CAARMS or depression scores.Interpretation: In keeping with other studies, omega-3 appears to have beneficial effects on ARMS and mood symptom severity but it increased transition to psychosis, which may reflect metabolic or developmental consequences of chronic poor nutrition in the population. Transition to psychosis was too rare to reveal a preventative effect of minocycline but minocycline did not improve symptom severity. ARMS symptom severity and transition to psychosis appear to have distinct pathogeneses which are differentially modulated by omega-3 supplementation.Funding: The study was funded by the Stanley Research Medical Institute.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 50 条
  • [31] The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Mirmasoumi, Golara
    Fazilati, Mohammad
    Foroozanfard, Fatemeh
    Vahedpoor, Zahra
    Mahmoodi, Samaneh
    Taghizadeh, Mohsen
    Esfeh, Nazanin Kazemi
    Mohseni, Maryam
    Karbassizadeh, Hassan
    Asemi, Zatollah
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2018, 126 (04) : 222 - 228
  • [32] The effect of dietary ω-3 fatty acids on coronary atherosclerosis -: A randomized, double-blind, placebo-controlled trial
    von Schacky, C
    Angerer, P
    Kothny, W
    Theisen, K
    Mudra, H
    ANNALS OF INTERNAL MEDICINE, 1999, 130 (07) : 554 - 562
  • [33] Omega-3 Fatty Acid Supplementation Does Not Reduce Risk of Atrial Fibrillation After Coronary Artery Bypass Surgery A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Saravanan, Palaniappan
    Bridgewater, Ben
    West, Annette L.
    O'Neill, Stephen C.
    Calder, Philip C.
    Davidson, Neil C.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2010, 3 (01): : 46 - 53
  • [34] Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children
    Carucci, Sara
    Romaniello, Roberta
    Demuru, Giovanni
    Curatolo, Paolo
    Grelloni, Clementina
    Masi, Gabriele
    Liboni, Francesca
    Mereu, Alessandra
    Contu, Paolo
    Lamberti, Marco
    Gagliano, Antonella
    Zuddas, Alessandro
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2022, 272 (08) : 1453 - 1467
  • [35] Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Freudenreich, O
    Herz, L
    Deckersbach, T
    Evins, AE
    Henderson, DC
    Cather, C
    Goff, DC
    PSYCHOPHARMACOLOGY, 2005, 181 (02) : 358 - 363
  • [36] Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    Lawrence Herz
    Thilo Deckersbach
    A. Eden Evins
    David C. Henderson
    Corinne Cather
    Donald C. Goff
    Psychopharmacology, 2005, 181 : 358 - 363
  • [37] ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study) A Randomized, Double-Blind, Placebo-Controlled Trial
    Torkildsen, Oivind
    Wergeland, Stig
    Bakke, Soren
    Beiske, Antonie G.
    Bjerve, Kristian S.
    Hovdal, Harald
    Midgard, Rune
    Lilleas, Finn
    Pedersen, Tom
    Bjornara, Bard
    Dalene, Froydis
    Kleveland, Grethe
    Schepel, Jan
    Olsen, Inge Christoffer
    Myhr, Kjell-Morten
    ARCHIVES OF NEUROLOGY, 2012, 69 (08) : 1044 - 1051
  • [38] Omega-3 Fatty Acids as a Treatment for Pediatric Depression. A Phase III, 36 Weeks, Multi-Center, Double-Blind, Placebo-Controlled Randomized Superiority Study
    Haberling, Isabelle
    Berger, Gregor
    Schmeck, Klaus
    Held, Ulrike
    Walitza, Susanne
    Baumgartner, Noemi
    Emery, Sophie
    Albermann, Mona
    Nalani, Kristin
    Pick, Oliver
    Di Gallo, Alain
    Strumberger, Michael
    Contin, Brigitte
    Mueller, Stefan
    Bachmann, Silke
    Wockel, Lars
    Heitzer, Simone
    Rhiner, Bruno
    Yamini, Amir
    Erb, Suzanne
    Schmid, Michael
    Mueller-Knapp, Ulrich
    Christodoulakis, Ioannis
    Seifert, Burkhardt
    Drechsler, Renate
    Grunblatt, Edna
    Hersberger, Martin
    Hartling, Ivan
    Brunner, Romuald
    Drewe, Jurgen
    Braun, Julia
    FRONTIERS IN PSYCHIATRY, 2019, 10
  • [39] Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial
    Felau, Sheylla M.
    Sales, Lucas P.
    Solis, Marina Y.
    Hayashi, Ana Paula
    Roschel, Hamilton
    Sa-Pinto, Ana Lucia
    Oliveira de Andrade, Danieli Castro
    Katayama, Keyla Y.
    Irigoyen, Maria Claudia
    Consolim-Colombo, Fernanda
    Bonfa, Eloisa
    Gualano, Bruno
    Benatti, Fabiana B.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [40] Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial
    Toktam Faghihi
    Adel Jahed
    Javad Mahmoudi-Gharaei
    Vandad Sharifi
    Shahin Akhondzadeh
    Padideh Ghaeli
    DARU Journal of Pharmaceutical Sciences, 20